

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/738,463	12/17/2003	Ernst-Wilhelm Schubert	71128	9591
23872 7590 07/30/2007 MCGLEW & TUTTLE, PC		·	EXAMINER	
P.O. BOX 9227	7	KOHARSKI, CHRISTOPHER		
SCARBOROU SCARBOROU	GH STATION GH, NY 10510-9227		ART UNIT	PAPER NUMBER
	·		3763	
•				
			MAIL DATE	DELIVERY MODE
			07/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

C
---

		Application No.	Applicant(s)		
Office Action Summary		10/738,463	SCHUBERT ET AL.		
		Examiner	Art Unit		
		Christopher D. Koharski	3763		
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address		
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in a solid part of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
2a)⊠	Responsive to communication(s) filed on <u>04 M</u> This action is <b>FINAL</b> . 2b) This Since this application is in condition for allower closed in accordance with the practice under E	action is non-final.			
Dispositi	on of Claims				
5)□ 6)⊠ 7)⊠ 8)□ Applicati	Claim(s) <u>1-19</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) <u>1-19</u> is/are rejected.  Claim(s) <u>1, 4 and 9</u> is/are objected to.  Claim(s) are subject to restriction and/or  on Papers	wn from consideration. r election requirement.			
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority ι	ınder 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
2) 🔲 Notic 3) 🔯 Infor	t(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) or No(s)/Mail Date 5/04/2007.	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	ate		

# **DETAILED ACTION**

## Response to Amendment

Examiner acknowledges the reply filed 5/04/2007 in which claims 1, 4, 6-10 have been amended and new claims 14-19 were added. Currently claims 1-19 are pending for examination in this application.

#### Information Disclosure Statement

The information disclosure statement (IDS) that was submitted on 5/04/2007 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner is considering the information disclosure statement.

### Specification

The disclosure is objected to because of the following informalities: It is the Examiner's position that Applicant has invoked sixth paragraph, means-plus-function language to define Applicant's invention. Therefore the Examiner requires the Applicant to amend the specification pursuant to 37 CFR 1.75(d) and MPEP 608.01(o) to explicitly state, with reference to the terms and phrases of the claim element, what structure, materials, and acts perform the function recited in the claim element. Please note that the MPEP clearly states, "Even if the disclosure implicitly sets forth the structure, materials, or acts corresponding to the means-(or step-) plus-function claim element in compliance with 35 U.S.C. 112, first and second paragraphs, the PTO may still require the applicant to amend the specification pursuant to 37 CFR 1.75(d) and MPEP 608.01(o)...". (Also see MPEP 2181 (Rev. 1, Feb.2000))

Appropriate correction is required.

Page 3

Art Unit: 3763

## Claim Objections

Claims 1,4 and 9 are objected to because of the following informalities: It is the Examiner's position that Applicant has evoked sixth paragraph, means-plus-function language to define Applicant's invention. Therefore the Examiner has objected to the claims for the reasons set forth above in the objection to the specification.

Appropriate correction is required.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-19 are rejected under 35 U.S.C. 102(b) as being anticipated by Prendergast (5,873,371). Prendergast discloses a patient drug recognition system.

Regarding claims 1-19, Prendergast discloses a device (6) for dispensing medical active ingredients comprising a micropump (140, 142, 144) with a computer controller (31) (col 8, ln 50-60) for evaluating data and controlling the micropumps, multiple modules with an upper and lower parts (near 132, 134, 136) with a coupling means and coupling receiving part (135, 164) capable of being coupled to an adjacent module and in series with a guiding structure (Figure 4), a code means for passing medical information and electrical signals (82, 84) (col 6, ln 25-60) (Figures 5-6b) including pins (90), a removable article (150), a fluid interface (near 128) connectable to a supply line (near 130) and base part (166, 168, 170) leading to a patient, a cartridge

Art Unit: 3763

(132, 134, 136) for receiving a medical active ingredient; and a delivery means for delivering (manifold near 130) the medical active ingredient from said cartridge to said fluid interface (Figures 1-8) with a solution container (128).

## Claim Rejections - 35 USC § 102

Claims 1-19 are rejected under 35 U.S.C. 102(b) as being anticipated by Kerns et al. (4,756,706). Kerns et al. discloses a centrally managed modular infusion pump system.

Regarding claims 1-19, Kerns et al. discloses a device (Figure 1) for dispensing medical active ingredients comprising a micropump (22) with a computer controller (14) (Figure 18) for evaluating data and controlling the micropumps, multiple modules with an upper and lower parts (22) with a coupling means and coupling receiving part (122, 124) capable of being coupled to an adjacent module and in series with a guiding structure (Figures 4a-4c), a code means for passing medical information and electrical signals (168) including pins (154), a removable article (50, 52), a fluid interface (near 54, 56) connectable to a supply line (near 52, 50) and base part (near 66) leading to a patient, a cartridge (100) for receiving a medical active ingredient; and a delivery means for delivering (manifold 40, 54, 56) the medical active ingredient from said cartridge to said fluid interface (Figures 1-18) with a solution container (28, 30, 36).

### Response to Arguments

Applicant's arguments with respect to claims 1-19 have been considered but are most in view of the new ground(s) of rejection necessitated by Applicant's amendment.

Application/Control Number: 10/738,463 Page 5

Art Unit: 3763

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher D. Koharski whose telephone number is 571-272-7230. The examiner can normally be reached on 7:30am to 4:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nick Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/738,463

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Date: 7)19/07

Cothines William

Christopher D. Koharski AU 3763

Page 6

CATHERINE S. WILLIAMS PRIMARY EXAMINER